Funded Project Details - FY2021
|Title:|| High-dose targeted and non-toxic IL-2 cytokine therapy|
Alexander S Krupnick
|Congressional District Code:
||Biomedical Laboratory R&D
|| April 2019 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
PROJECT SUMMARY/ABSTRACT Systemic administration of high-dose IL-2 has been used since the 1980’s as an FDA-approved immunotherapy for metastatic cancer. Despite the fact that up to 9% of patients treated with high dose IL-2 achieve a durable, long term response, this therapy is rarely used today due to significant life-threatening complications. Such complications occur due to IL-2 activation of vascular endothelium, resulting in systemic capillary leak, as well as other adverse effects associ...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.